This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dawson, A. Articles by Struthers, A. D Search for Related Content PubMed PubMed Citation Articles by Dawson, A. Articles by Struthers, A. D Social Bookmarking                         What's this?

Review: Vasopeptidase inhibitors in heart failure

Department of Clinical Pharmacology & Therapeutics, University of Dundee, Ninewells Hospital, Dundee, DD1 9SY Scotland

Allan D Struthers

Department of Clinical Pharmacology & Therapeutics, University of Dundee, Ninewells Hospital, Dundee, DD1 9SY Scotland, a.d.struthers@ dundee.ac.uk

Considerable attention has recently focused on the vasopeptidase inhibitors (VPI), a new class of drug that combines angiotensin-converting enzyme (ACE) inhibitor activity with inhibition of natriuretic peptide breakdown. In theory, a drug with these properties may be beneficial both in hypertension and in heart failure. Whilst the efficacy of VPIs in hypertension has been consistently demonstrated in pre-clinical and clinical studies, the role of VPIs, if any, in heart failure is less clear, since numerous small studies have produced conflicting results. Furthermore, preliminary results from the recently completed Omapatrilat Versus Enalapril Randomised Trial of Utility in Reducing Events (OVERTURE) study have failed to establish the VPI, omapatrilat, as a first line therapy in the treatment of chronic heart failure. We review the literature on VPIs in heart failure and discuss possible reasons for the reported lack of benefit over ACE inhibitors.

Key Words: vasopeptidase inhibitors • heart failure • omapatrilat • natriuretic peptides

Journal of Renin-Angiotensin-Aldosterone System, Vol. 3, No. 3, 156-159 (2002)
DOI: 10.3317/jraas.2002.035


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Clerico, F. A. Recchia, C. Passino, and M. Emdin Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H17 - H29. [Abstract] [Full Text] [PDF]